title: Plasma protein carbonyl levels and breast cancer risk.
abstract: To study the role of oxidative stress in breast cancer risk, we analysed plasma levels of protein carbonyls in 1050 cases and 1107 controls. We found a statistically significant trend in breast cancer risk in relation to increasing quartiles of plasma protein carbonyl levels (OR = 1.2, 95% CI = 0.9-1.5; OR = 1.5, 95% CI = 1.2-2.0; OR = 1.6, 95% CI = 1.2-2.1, for the 2(nd), 3(rd) and 4(th) quartile relative to the lowest quartile, respectively, P for trend = 0.0001). The increase in risk was similar for younger (<50 years) and older women, more pronounced among women with higher physical activity levels (0.7 hrs/week for 4(th) quartile versus lowest quartile OR = 2.0, 95% CI = 1.4-3.0), higher alcohol consumption (> or = 15 grams/day for 4(th) quartile versus lowest quartile OR = 2.3, 95% CI = 1.1-4.7), and hormone replacement therapy use (HRT, OR = 2.6, 95% CI = 1.6-4.4 for 4(th) quartile versus lowest quartile). The multiplicative interaction terms were statistically significant only for physical activity and HRT. The positive association between plasma protein carbonyl levels and breast cancer risk was also observed when the analysis was restricted to women who had not received chemotherapy or radiation therapy prior to blood collection. Among controls, oxidized protein levels significantly increased with cigarette smoking and higher fruit and vegetable consumption, and decreased with alcohol consumption >30 grams per day. Women with higher levels of plasma protein carbonyl and urinary 15F(2t)-isoprostane had an 80% increase in breast cancer risk (OR = 1.8, 95% CI = 1.2-2.6) compared to women with levels below the median for both markers of oxidative stress. In summary, our results suggest that increased plasma protein carbonyl levels may be associated with breast cancer risk.
authors.affiliation: Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA. prossner@biomed.cas.cz
authors.forename: Pavel
authors.initials: P
authors.lastname: Rossner
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: Terry
authors.forename: Marilie D
authors.initials: MD
authors.lastname: Gammon
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Agrawal
authors.forename: Fang Fang
authors.initials: FF
authors.lastname: Zhang
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Ferris
authors.forename: Susan L
authors.initials: SL
authors.lastname: Teitelbaum
authors.forename: Sybil M
authors.initials: SM
authors.lastname: Eng
authors.forename: Mia M
authors.initials: MM
authors.lastname: Gaudet
authors.forename: Alfred I
authors.initials: AI
authors.lastname: Neugut
authors.forename: Regina M
authors.initials: RM
authors.lastname: Santella
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology*; D016001:Confidence Intervals; D028441:F2-Isoprostanes / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D050050:Protein Carbonylation; D012307:Risk Factors
chemical_list: D028441:F2-Isoprostanes